Truist Securities Maintains Buy on Medline, Lowers Price Target to $47

Medline

Medline

MDLN

0.00

Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ: MDLN) with a Buy and lowers the price target from $56 to $47.